-

Inversago Pharma to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference to Be Held on April 20-21, 2021

MONTREAL--(BUSINESS WIRE)--Inversago Pharma Inc., the peripheral CB1 blockade company, today announced that François Ravenelle, PhD, CEO and Founder, will be presenting at the Bloom Burton & Co. Healthcare Investor Conference.

Details are as follows:

Date: Wednesday, April 21, 2021
Time: 4 pm ET
Format: 30-minute live virtual presentation, including Q&A

About the Conference
The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings. For more information or registration, please visit bloomburton.com.

About Inversago Pharma
Inversago Pharma is a clinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Prader-Willi Syndrome (PWS), non-alcoholic steatohepatitis (NASH), type 1 diabetes (T1D) and diabetic nephropathy. For more information, visit inversago.com.

Contacts

François Ravenelle, PhD
CEO & Founder
Inversago Pharma inc.
info@inversago.com

Industry:

Inversago Pharma Inc.

Details
Headquarters: Montreal, QC - Canada
CEO: Francois Ravenelle
Employees: 16
Organization: PRI
Release Summary
Inversago Pharma to present at upcoming Bloom Burton & Co. Healthcare Investor Conference to be held on April 20-21, 2021
Release Versions
EnglishFrench

Contacts

François Ravenelle, PhD
CEO & Founder
Inversago Pharma inc.
info@inversago.com

Social Media Profiles
Inversago Pharma/LinkedIn
More News From Inversago Pharma Inc.

Inversago Pharma Presents Data from Phase 1b Trial of INV-202, a Peripheral CB1r Blocker for Metabolic Syndrome, at the 83rd American Diabetes Association Scientific Sessions

MONTREAL & SAN DIEGO--(BUSINESS WIRE)--Inversago Pharma Inc. (“Inversago”), a leader in the development of peripherally-acting CB1 receptor (CB1r) blockers to address complications associated with metabolic and fibrotic diseases, today announced data from its Phase 1b trial for INV-202 to be presented in a poster session at the 83rd American Diabetes Association Scientific Sessions (ADA) in San Diego. INV-202 is a potential first-in-class, peripherally-acting CB1r blocker, being developed to tr...

Inversago Pharma to Present Data from Phase 1b Trial of INV-202, a Peripheral CB1r Blocker for Metabolic Syndrome, at the 83rd American Diabetes Association Scientific Sessions

MONTREAL, Québec--(BUSINESS WIRE)--Inversago Pharma Inc. (“Inversago”), a leader in the development of peripherally-acting CB1 receptor blockers to address complications associated with metabolic and fibrotic diseases, today announced that it will present data from the Phase 1b trial for INV-202, at the 83rd American Diabetes Association Scientific Sessions taking place on June 23-26, 2023, in San Diego, California. INV-202 is a potential first-in-class, peripheral CB1r blocker, being developed...

Inversago Pharma Announces New Data to be Presented at the 2023 American Thoracic Society International Conference

MONTREAL--(BUSINESS WIRE)--Inversago Pharma Inc. (“Inversago”), a leader in the development of peripherally-acting CB1 receptor (CB1r) blockers to address complications associated with metabolic and fibrotic diseases, today announced positive results from a proof-of-concept study of INV-202 in a mouse model of obese asthma at the American Thoracic Society (ATS) International Conference taking place from May 19-24, 2023, in Washington, D.C. In an oral presentation, Carolyn R. Morris, PhD, Facult...
Back to Newsroom